Literature DB >> 11720456

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere).

G S Wang1, K Y Yang, R P Perng.   

Abstract

4 patients with advanced non-small-cell lung cancer (NSCLC) treated with docetaxel developed life-threatening pneumonitis requiring mechanical ventilation. Docetaxel (30-60 mg x m(-2), according to a different protocol) was infused within one hour with standard premedications. One patient's pneumonitis occurred 5 days after the first dose of docetaxel, and that of the other 3 between the 2nd and 6th cycles. Based on the clinical course, radiological findings of an interstitial pneumonitis, and exclusion of other possible resultant causes, including metastatic cancer, radiation pulmonary injury, infection, or connective tissue disease, hypersensitivity pneumonitis was diagnosed. The patients were treated with hydrocortisone at 1200 mg per day or methylprednisolone at 240 mg per day. Although 3 of the 4 had a partial improvement in lung oxygenation, all patients' conditions of hypersensitivity pneumonitis persisted and were complicated by other events, such as hospital-acquired infection and tension pneumothorax. The presence of this unusual hypersensitivity pneumonitis, which was so severe as to be life-threatening and refractory to high-dose corticosteroid therapy, should be taken into account during docetaxel treatment. Copyright 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720456      PMCID: PMC2375237          DOI: 10.1054/bjoc.2001.2071

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Docetaxel and interstitial pulmonary injury.

Authors:  M Merad; A Le Cesne; P Baldeyrou; B Mesurolle; T Le Chevalier
Journal:  Ann Oncol       Date:  1997-02       Impact factor: 32.976

2.  Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel.

Authors:  V G Schweitzer; G J Juillard; C L Bajada; R G Parker
Journal:  Cancer       Date:  1995-09-15       Impact factor: 6.860

3.  Provocation test coupled with bronchoalveolar lavage in diagnosis of propranolol-induced hypersensitivity pneumonitis.

Authors:  G M Akoun; B J Milleron; C M Mayaud; D Tholoniat
Journal:  Am Rev Respir Dis       Date:  1989-01

4.  [Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases].

Authors:  B Etienne; M Pérol; P Nesme; S Vuillermoz; G Robinet; J C Guérin
Journal:  Rev Mal Respir       Date:  1998-04       Impact factor: 0.622

5.  Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.

Authors:  H Kunitoh; K Watanabe; T Onoshi; K Furuse; H Niitani; T Taguchi
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

6.  Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group.

Authors:  K Furuse; N Naka; M Takada; E Kinuwaki; S Kudo; Y Takada; M Yamakido; H Yamamoto; M Fukuoka
Journal:  Oncology       Date:  1997 Jul-Aug       Impact factor: 2.935

7.  Paclitaxel-induced acute bilateral pneumonitis.

Authors:  A Khan; D McNally; P J Tutschka; S Bilgrami
Journal:  Ann Pharmacother       Date:  1997-12       Impact factor: 3.154

8.  Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis.

Authors:  G M Akoun; H A Liote; F Liote; S Gauthier-Rahman; D Kuntz
Journal:  Chest       Date:  1990-02       Impact factor: 9.410

9.  Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy.

Authors:  K Fujimori; A Yokoyama; Y Kurita; K Uno; N Saijo
Journal:  Oncology       Date:  1998 Jul-Aug       Impact factor: 2.935

10.  Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.

Authors:  T Tamura; Y Sasaki; Y Nishiwaki; N Saijo
Journal:  Jpn J Cancer Res       Date:  1995-12
View more
  21 in total

1.  Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.

Authors:  Masahiro Tsuboi; Thierry Le Chevalier
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment.

Authors:  C Grande; M J Villanueva; G Huidobro; J Casal
Journal:  Clin Transl Oncol       Date:  2007-09       Impact factor: 3.405

3.  Perivascular carotid inflammation: an unusual case of carotidynia.

Authors:  Lama Azar; Harry D Fischer
Journal:  Rheumatol Int       Date:  2009-12-20       Impact factor: 2.631

4.  Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.

Authors:  J Boulanger; J N Boursiquot; G Cournoyer; J Lemieux; M S Masse; K Almanric; M P Guay
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

5.  Interstitial pneumonia associated with neoadjuvant chemotherapy in breast cancer.

Authors:  Hidemi Kawajiri; Tsutomu Takashima; Naoyoshi Onoda; Shinichiro Kashiwagi; Tetsurou Ishikawa; Kosei Hirakawa
Journal:  Mol Clin Oncol       Date:  2013-03-05

6.  Pulmonary toxicity in patients receiving docetaxel chemotherapy.

Authors:  Perran F Yumuk; Umut Kefeli; Berrin Ceyhan; Faysal Dane; Basak T Eroglu; Mahmut Gumus; Devrim Cabuk; Gul Basaran; Ufuk Abacioglu; Nazım S Turhal
Journal:  Med Oncol       Date:  2009-12-25       Impact factor: 3.064

Review 7.  The epidemiology of interstitial lung disease and its association with lung cancer.

Authors:  G Raghu; F Nyberg; G Morgan
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

Review 8.  Understanding the mechanisms of drug-associated interstitial lung disease.

Authors:  T Higenbottam; K Kuwano; B Nemery; Y Fujita
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

Review 9.  Interstitial lung disease associated with drug therapy.

Authors:  P Camus; S Kudoh; M Ebina
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

10.  Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management.

Authors:  P Camus
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.